NASDAQ
26.00USD
+0.59 (+2.32%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
420.7M
P/E
—
EPS
—
Beta
0.00
52W range
17.31-26.5
Day range
24.08–26.50
Open
25.45
Prev close
25.41
Volume
119.6K
Avg volume
402.2K
Dividend
0.00
IPO
2026-07-24
https://seekingalpha.com/article/4925530-crispr-biotech-pops-44-percent-more-names-join-ipo-pipeline · 7/25/2026+0.80
https://www.globenewswire.com/news-release/2026/07/24/3332675/0/en/Scribe-Therapeutics-Announces-Pricing-of-Upsized-Initial-Public-Offering.html · 7/24/2026+1.00
Scribe Therapeutics is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. The company engineers proprietary technologies to target the genetic drivers of disease, with an initial focus on atherosclerotic cardiovascular disease (ASCVD), aiming to shift treatment from chronic care to preventative intervention.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
